| |
Number
|
Percent
|
|---|
|
PB regimen (n = 51)
|
|
CR
|
0
|
0.0
|
|
PR
|
26
|
51.0
|
|
SD
|
20
|
39.2
|
|
PD
|
5
|
9.8
|
|
NE
|
0
|
0.0
|
|
ORR (CR + PR)
|
26
|
51.0
|
|
95% CI
|
36.6–65.3
| |
|
DCR (CR + PR + SD)
|
46
|
90.2
|
|
95% CI
|
78.6–96.7
| |
|
Maintenance treatment with eribulin (n = 45)
|
|
CR
|
0
|
0.0
|
|
PR
|
29
|
64.4
|
|
SD
|
13
|
28.9
|
|
PD
|
3
|
6.7
|
|
ORR (CR + PR)
|
29
|
64.4
|
|
95% CI
|
48.8–78.1
| |
|
DCR (CR + PR + SD)
|
42
|
93.3
|
|
95% CI
|
81.7–98.6
| |
- BP bevacizumab + paclitaxel, CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate, CI confidence interval
